 Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos product candidate, acoramidis, a potential best-in-class therapy for patients with amyloidosis cardiomyopathy ATTR-CM 